No Detail Found!

SHORT-TERM EFFICACY OF INTRAVITREAL PATIZRA® (RANIBIZUMAB) IN TREATMENT NAIVE PATIENTS- REAL WORLD EVIDENCE IN PAKISTAN

Author(s)
Hajra Arshad Malik Amanat Eye Hospital Islamabad,Pakistan
Rayyan Sabih Amanat Eye Hospital Islamabad,Pakistan
Hina Khan Amanat Eye Hospital Islamabad,Pakistan
Muhammad Umair Combined Military Hospital Rawalpindi,Pakistan
Muhammad Asif Government College University Faisalabad ,Pakistan
Aamir Asrar Amanat Eye Hospital Islamabad,Pakistan
Maha Asrar Amanat Eye Hospital Islamabad,Pakistan
Abstract
Background: Macular oedema is a final common pathway of a multitude of both ocular and systemic insults. This study was conducted to evaluate the short-term efficacy and safety of intraocular Ranibizumab in patients with macular oedema in a 'real-world' setting in Pakistan. Methods: A prospective multicenter study conducted at Amanat Eye Hospitals in Islamabad and Rawalpindi from 1st August 2018 to 1st November 2019. Forty-four eyes of 34 patients with macular oedema were treated with monthly intravitreal Ranibizumab (Patizra®) injections for three consecutive months. Best-corrected visual acuity (BCVA), and optical coherence tomography (OCT) parameters including central retinal thickness (CRT) and macular volume were assessed prior to the injections and then 4 weeks post the final injection and compared. Results: BCVA improved from logMAR 0.61±0.40 at baseline to 0.27±0.35 four weeks after the third intravitreal injection. CRT decreased from 428.54±187.06 µm at baseline to 364.50±170.49 µm. Macular volume showed a non-significant decrease from 9.97±3.19 mm3 at baseline to 9.22±2.68 mm3 four weeks after the third intravitreal injection. No systemic or ocular complications were observed during the course of the study. Conclusion: Treatment with intravitreal Patizra® injections was found safe and resulted in clinically and statistically significant improvement in visual acuity and the SD-OCT parameter of central retinal thickness in patients with macular oedema secondary to various retinal pathologies. There was no significant decrease in the macular volume.
Publication Details
Page(s) 613-616
Published Journal: Journal of Ayub Medical College, Volume: 34, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Retinal Vein Occlusion, Ranibizumab, Macular Degeneration, Diabetic Retinopathy., Macular Oedema
0

Citations

0

Downloads

55

Views